Table 2. Characteristics of the AUT-MuSC-19 cohort.
| n = 126 | |
|---|---|
| Femalea | 90 (71.4) |
| Age (years)b,c | 43.2 (13.4; 21–79) |
| BMI c | 24.1 (17.4–41.0) |
| Smokersa | 17 (3.5) |
| Ethnicitya | |
| Caucasiana | 123 (97.6) |
| Othera | 3 (2.4) |
| No of comorbidities associated with increased COVID-19 morbidityc* | 0 (0–5) |
| Disease duration (years) b | 12.0 (9.3) |
| Disease coursea | |
| RRMSa | 98 (77.8) |
| SPMSa | 19 (15.1) |
| PPMSa | 9 (7.1) |
| EDSSc | 2.0 (0–8.5) |
| On DMTa | 90 (71.4) |
| IM-DMT | 48 (38.1) |
| Interferon-betaa | 6 (4.8) |
| Glatiramer acetatea | 11 (8.7) |
| Dimethyl fumaratea | 19 (15.1) |
| Teriflunomidea | 2 (1.6) |
| Natalizumaba | 10 (7.9) |
| IS-DMT | 41 (32.5) |
| Fingolimoda | 16 (12.7) |
| Ocrelizumab/Rituximaba | 12 (9.5) |
| Alemtuzumaba | 2 (1.6) |
| Cladribine | 2 (1.6) |
| Azathioprina | 1 (0.8) |
| Lymphopenia at last lab before SARS-CoV2 infectiona** | 19 (18.4) |
| Grade 3 or lowera | 7 (6.8) |
BMI: body mass index. DMT: disease modifying treatment. EDSS: Expanded Disability Status Scale. IM-DMT: Immunomodulating DMT = dimethyl fumarate, glatiramer acetate, interferon beta preparations, natalizumab, and teriflunomide. IS-DMT: Immunosuppressive DMT = alemtuzumab, cladribine, fingolimod, ocrelizumab or rituximab. MS: multiple sclerosis. PPMS: primary progressive MS. RRMS: relapsing-remitting MS. SPMS: secondary progressive MS.
aabsolute number and percentage.
bmean and standard deviation.
cmedian and minimum-maximum range.
*defined as cardiovascular diseases, chronic obstructive pulmonary disease, chronic kidney disease, diabetes and concurrent malignancy.
**available from 103 patients.